New pill aims to tackle heart failure and obesity together
NCT ID NCT06820099
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called HRS-7535 in 225 adults who have both heart failure (with mildly reduced or preserved pumping ability) and obesity. Participants will receive either the drug or a placebo for 36 weeks to see if it helps with weight loss and reduces inflammation. The goal is to find a new treatment option that manages both conditions at once.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact